1262413-92-2

Upstream product

• 42521-10-8 2-chloro-6-methoxyisonicotinic acid methyl ester 
• 63076-51-7 cyclopentane boronic acid 
• 5398-44-7 2,6-dichloropyridine-4-carboxylic acid 

Downstream Products

• 1122089-67-1 2-cyclopentyl-6-methoxypyridine-4-carboxylic acid 
• 1262414-36-7 4-[5-(4-benzyloxy-3-ethyl-5-methylphenyl)-[1,3,4]oxadiazol-2-yl]-2-cyclopentyl-6-methoxypyridine 
• 1262414-37-8 4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,3,4]oxadiazol-2-yl]-2-ethyl-6-methylphenol 
• 1262413-96-6 N'-(2-cyclopentyl-6-methoxypyridine-4-carbonyl)hydrazinecarboxylic acid benzyl ester 
• 1391465-64-7 2-(2-chloro-4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)acetaldehyde 
• 1391464-87-1 3-((2-(2-chloro-4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)ethyl)amino)propanoic acid 
• 1391464-10-0 3-(2-{4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}ethylamino)propionic acid 
• 1391465-35-2 2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)ethanol 
• 1391465-37-4 2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)ethyl methanesulfonate 
• 1391465-38-5 ethyl 3-((2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)ethyl)amino)propanoate 
• 1391465-39-6 (S)-5-(2-cyclopentyl-6-methoxypyridin-4-yl)-3-(3-ethyl-5-methyl-4-(oxiran-2-ylmethoxy)phenyl)-1,2,4-oxadiazole 
• 1391464-17-7 {4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}acetic acid 
• 1391465-41-0 (S)-2-((3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)amino)acetic acid ethyl ester 
• 1391464-24-6 ((S)-3-{4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}-2-hydroxypropylamino)acetic acid 

Relevant academic research and scientific papers

S1P1 AGONIST AND APPLICATION THEREOF

The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same.

Practical Synthesis of a S1P Receptor 1 Agonist via a Guareschi-Thorpe Reaction

A practical synthesis of S1P receptor 1 agonist ACT-334441 (1) through late-stage convergent coupling of two key intermediates is described. The first intermediate is 2-cyclopentyl-6-methoxyisonicotinic acid whose skeleton was built from 1-cyclopentylethanone, ethyl oxalate, and cyanoacetate in a Guareschi-Thorpe reaction in 42% yield over five steps. The second, chiral intermediate, is a phenol ether derived from enantiomerically pure (R)-isopropylidene glycerol ((R)-solketal) and 3-ethyl-4-hydroxy-5-methylbenzonitrile in 71% yield in a one-pot reaction. The overall sequence entails 18 chemical steps with 10 isolated intermediates. All raw materials are cheap and readily available in bulk quantities, the reaction conditions match with standard pilot plant equipment, and the route reproducibly afforded 3-20 kg of 1 in excellent purity and yield for clinical studies.

Novel S1P1 receptor agonists - Part 5: From amino-to alkoxy-pyridines

In a previous communication we reported on the discovery of aminopyridine 1 as a potent, selective and orally active S1P1 receptor agonist. More detailed studies revealed that this compound is phototoxic in vitro. As a result of efforts aiming at eliminating this undesired property, a series of alkoxy substituted pyridine derivatives was discovered. The photo irritancy factor (PIF) of these alkoxy pyridines was significantly lower than the one of aminopyridine 1 and most compounds were not phototoxic. Focused SAR studies showed, that 2-, 3-, and 4-pyridine derivatives delivered highly potent S1P1 receptor agonists. While the 2-pyridines were clearly more selective against S1PR3, the corresponding 3- or 4-pyridine analogues showed significantly longer oral half-lives and as a consequence longer pharmacological duration of action after oral administration. One of the best compounds, cyclopentoxy-pyridine 45b lacked phototoxicity, showed EC50 values of 0.7 and 140 nM on S1PR1 and S1PR3, respectively, and maximally reduced the blood lymphocyte count for at least 24 h after oral administration of 10 mg/kg to Wistar rats.

2-METHOXY-PYRIDIN-4-YL-DERIVATIVES

The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

2-METHOXY-PYRIDIN-4-YL DERIVATIVES

The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.